Please assess the completion status of the following clinical trial:

Trial Title: Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adults healthy volunteers and adult patients with anterior uveitis who wish to participate.~Exclusion Criteria:~* Patients with anterior uveitis who have other systemic diseases/conditions not related to their anterior uveitis, like high blood pressure, diabetes or epilepsy.~* Patients with ocular comorbidity or compliactions to their anterior uveitis, such as elevated ocular pressure or glaucoma.~* Previous or current macular edema or other posterior segment complications related to uveitis.~* Subjects with visual acuity worse than 0.8~* Subjects/patients with cataracts or other ocular media opacities~* Subjects/patients who are allergic to local anesthesia or mydriatics.~* Subjects/patients with high myopia/hyperopia~* Subjects/patients who have had intraocular surgery, although previous uncomplicated LASIK correction for low-grade myopia were accepted.~* Subjects/patients who cooperate poorly.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Diclofenac (Type: EXPERIMENTAL): Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
- Dexamethasone (Type: EXPERIMENTAL): Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).